Whereas the mean overall survival time was shortened in the OSCC cohort with higher CHRNA5 mRNA levels compared to cohorts with other combined signatures (Figure 2A), the mean time to cancer recurrence did not differ between the OSCC and the non-OSCC cohorts with high CHRNA5 transcript levels (Figure 2B). Here, CHRNA5 is linked to cancer.